RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function.
Products / Markets. The company’s RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company is also developing a propriety, next-generation injection device (RCI) for optimal clinical delivery. Each condition is related to a deficit of a specific cell type which we believe is critical to the restoration of normal function.
Technology / IP. Innovative technology protected by both patents (issued and filed) and trade secrets on the cell isolation, product composition, manufacturing and clinical applications.
Partnerships. Shiseido has an exclusive license for RCH-01 in certain Asian countries including Japan, China and South Korea. The company is actively engaging potential partners for its other products.
Milestones. Management launched a clearly defined 18-month value creation plan in Q1 2015. The Company is launching multiple clinical trials anticipated in 2015 in addition to Shiseido’s own clinical trial of RCH-01 and the device in late prototype development which includes clinical data from two trials, launch of other trials, execution of other licensing deals, a healthier cash position, CE mark for the RCI injector device, multiple manufacturing improvements, and specific research programs targeting other products and applications.